SMO ClinPlus CO.,LTD.

SZSE:301257 Stock Report

Market Cap: CN¥2.4b

SMO ClinPlusLTD Past Earnings Performance

Past criteria checks 1/6

SMO ClinPlusLTD has been growing earnings at an average annual rate of 28.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 21.2% per year. SMO ClinPlusLTD's return on equity is 9.3%, and it has net margins of 13.1%.

Key information

28.3%

Earnings growth rate

21.2%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate21.2%
Return on equity9.3%
Net Margin13.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders

Nov 06
Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders

SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

May 05
SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

Recent updates

Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders

Nov 06
Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders

SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%

Sep 30
SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%

Little Excitement Around SMO ClinPlus CO.,LTD.'s (SZSE:301257) Earnings As Shares Take 37% Pounding

Jun 06
Little Excitement Around SMO ClinPlus CO.,LTD.'s (SZSE:301257) Earnings As Shares Take 37% Pounding

SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

May 05
SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

Revenue & Expenses Breakdown

How SMO ClinPlusLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301257 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248101066735
30 Jun 248061286535
31 Mar 247871326337
31 Dec 237601356135
30 Sep 237291355434
30 Jun 236901155434
31 Mar 23621885232
01 Jan 23586725632
30 Sep 22542525229
30 Jun 22523504926
31 Mar 22528585329
31 Dec 21503584021
30 Sep 21472586730
30 Jun 21421533817
31 Mar 21373464415
31 Dec 20335354415
31 Dec 19304522416
31 Dec 18193301712
30 Sep 18172291211
30 Jun 1814726165
31 Mar 1813223163
31 Dec 1711620115
30 Sep 179814103
30 Jun 17809101
31 Mar 1772890
31 Dec 1663880
31 Dec 1542-14240

Quality Earnings: 301257 has a high level of non-cash earnings.

Growing Profit Margin: 301257's current net profit margins (13.1%) are lower than last year (18.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301257's earnings have grown significantly by 28.3% per year over the past 5 years.

Accelerating Growth: 301257's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301257 had negative earnings growth (-21.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Return on Equity

High ROE: 301257's Return on Equity (9.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies